Wedmont Private Capital Purchases 929 Shares of Vertex Pharmaceuticals Incorporated $VRTX

by · The Cerbat Gem

Wedmont Private Capital increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 21.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,284 shares of the pharmaceutical company’s stock after purchasing an additional 929 shares during the quarter. Wedmont Private Capital’s holdings in Vertex Pharmaceuticals were worth $2,531,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of VRTX. Brighton Jones LLC lifted its position in Vertex Pharmaceuticals by 15.0% in the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after purchasing an additional 579 shares during the period. Westwood Holdings Group Inc. bought a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at $1,275,000. Waverly Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals by 632.5% during the fourth quarter. Waverly Advisors LLC now owns 3,948 shares of the pharmaceutical company’s stock valued at $1,590,000 after acquiring an additional 3,409 shares during the period. Mpwm Advisory Solutions LLC bought a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at $40,000. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in shares of Vertex Pharmaceuticals by 195.7% during the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 127,324 shares of the pharmaceutical company’s stock valued at $51,273,000 after acquiring an additional 84,266 shares during the period. 90.96% of the stock is owned by institutional investors.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs acquired 5,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were acquired at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This trade represents a 12.50% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Trading Down 1.1%

Shares of VRTX opened at $387.15 on Thursday. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.88. The stock has a market cap of $99.26 billion, a P/E ratio of 27.67 and a beta of 0.44. The stock’s 50-day moving average price is $418.00 and its two-hundred day moving average price is $451.75.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $2.94 billion for the quarter, compared to analysts’ expectations of $2.90 billion. During the same quarter in the previous year, the business posted ($12.83) EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Evercore ISI cut their price objective on Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a report on Thursday, September 11th. JPMorgan Chase & Co. lifted their price objective on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an “overweight” rating in a report on Monday, July 14th. HC Wainwright cut their price objective on Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating for the company in a report on Tuesday, August 5th. Stifel Nicolaus cut their price objective on Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating for the company in a report on Tuesday, August 5th. Finally, BMO Capital Markets set a $530.00 price objective on Vertex Pharmaceuticals and gave the company an “outperform” rating in a report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and thirteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $496.05.

Check Out Our Latest Research Report on Vertex Pharmaceuticals

About Vertex Pharmaceuticals

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Featured Articles

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).